276 related articles for article (PubMed ID: 36160452)
1. Macrophage-targeted nanomedicine for the diagnosis and management of atherosclerosis.
Hu PP; Luo SX; Fan XQ; Li D; Tong XY
Front Pharmacol; 2022; 13():1000316. PubMed ID: 36160452
[TBL] [Abstract][Full Text] [Related]
2. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis.
Chen W; Schilperoort M; Cao Y; Shi J; Tabas I; Tao W
Nat Rev Cardiol; 2022 Apr; 19(4):228-249. PubMed ID: 34759324
[TBL] [Abstract][Full Text] [Related]
3. Advances of nanomedicine in treatment of atherosclerosis and thrombosis.
Mao Y; Ren J; Yang L
Environ Res; 2023 Dec; 238(Pt 2):116637. PubMed ID: 37482129
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Microenvironment of Vulnerable Atherosclerotic Plaques: An Emerging Diagnosis and Therapy Strategy for Atherosclerosis.
Zhang S; Liu Y; Cao Y; Zhang S; Sun J; Wang Y; Song S; Zhang H
Adv Mater; 2022 Jul; 34(29):e2110660. PubMed ID: 35238081
[TBL] [Abstract][Full Text] [Related]
5. Molecularly targeted nanomedicine enabled by inorganic nanoparticles for atherosclerosis diagnosis and treatment.
Zhang X; Centurion F; Misra A; Patel S; Gu Z
Adv Drug Deliv Rev; 2023 Mar; 194():114709. PubMed ID: 36690300
[TBL] [Abstract][Full Text] [Related]
6. Application of targeted therapy strategies with nanomedicine delivery for atherosclerosis.
Ou LC; Zhong S; Ou JS; Tian JW
Acta Pharmacol Sin; 2021 Jan; 42(1):10-17. PubMed ID: 32457416
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances in Managing Atherosclerosis via Nanomedicine.
Chan CKW; Zhang L; Cheng CK; Yang H; Huang Y; Tian XY; Choi CHJ
Small; 2018 Jan; 14(4):. PubMed ID: 29239134
[TBL] [Abstract][Full Text] [Related]
8. Macrophage-targeted Nanomedicine for Sepsis: Diagnosis and Therapy.
Yang L; Lou X; Hao S; Zhou L; Hou Y
Curr Pharm Des; 2023; 29(26):2036-2049. PubMed ID: 37670701
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicine Approaches for Advanced Diagnosis and Treatment of Atherosclerosis and Related Ischemic Diseases.
Hu B; Boakye-Yiadom KO; Yu W; Yuan ZW; Ho W; Xu X; Zhang XQ
Adv Healthc Mater; 2020 Aug; 9(16):e2000336. PubMed ID: 32597562
[TBL] [Abstract][Full Text] [Related]
10. Nano-Systems for Advanced Therapeutics and Diagnosis of Atherosclerosis.
Gaurav C; Saurav B; Goutam R; Goyal AK
Curr Pharm Des; 2015; 21(30):4498-508. PubMed ID: 26377651
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology for Targeted Therapy of Atherosclerosis.
Hossaini Nasr S; Huang X
Front Pharmacol; 2021; 12():755569. PubMed ID: 34867370
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicine in the Diagnosis and Treatment of Atherosclerosis-A Systematic Review.
Vaidyanathan K; Gopalakrishnan S
Cardiovasc Hematol Disord Drug Targets; 2017; 17(2):119-131. PubMed ID: 28925905
[TBL] [Abstract][Full Text] [Related]
13. Atherosclerosis and Nanomedicine Potential: Current Advances and Future Opportunities.
Jiang F; Zhu Y; Gong C; Wei X
Curr Med Chem; 2020; 27(21):3534-3554. PubMed ID: 30827225
[TBL] [Abstract][Full Text] [Related]
14. Targeting macrophages using nanoparticles: a potential therapeutic strategy for atherosclerosis.
Zang X; Cheng M; Zhang X; Chen X
J Mater Chem B; 2021 Apr; 9(15):3284-3294. PubMed ID: 33881414
[TBL] [Abstract][Full Text] [Related]
15. A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis.
Alaarg A; Senders ML; Varela-Moreira A; Pérez-Medina C; Zhao Y; Tang J; Fay F; Reiner T; Fayad ZA; Hennink WE; Metselaar JM; Mulder WJM; Storm G
J Control Release; 2017 Sep; 262():47-57. PubMed ID: 28700897
[TBL] [Abstract][Full Text] [Related]
16. The choice of targets and ligands for site-specific delivery of nanomedicine to atherosclerosis.
Zia A; Wu Y; Nguyen T; Wang X; Peter K; Ta HT
Cardiovasc Res; 2020 Nov; 116(13):2055-2068. PubMed ID: 32077918
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution of Nanostructured Lipid Carriers in Mice Atherosclerotic Model.
Devel L; Almer G; Cabella C; Beau F; Bernes M; Oliva P; Navarro F; Prassl R; Mangge H; Texier I
Molecules; 2019 Sep; 24(19):. PubMed ID: 31561608
[TBL] [Abstract][Full Text] [Related]
18. A Nano-Emulsion Platform Functionalized with a Fully Human scFv-Fc Antibody for Atheroma Targeting: Towards a Theranostic Approach to Atherosclerosis.
Bonnet S; Prévot G; Mornet S; Jacobin-Valat MJ; Mousli Y; Hemadou A; Duttine M; Trotier A; Sanchez S; Duonor-Cérutti M; Crauste-Manciet S; Clofent-Sanchez G
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068875
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicine for Diagnosis and Treatment of Atherosclerosis.
Cheng J; Huang H; Chen Y; Wu R
Adv Sci (Weinh); 2023 Dec; 10(36):e2304294. PubMed ID: 37897322
[TBL] [Abstract][Full Text] [Related]
20. The Function, Regulation and Mechanism of Programmed Cell Death of Macrophages in Atherosclerosis.
Liu C; Jiang Z; Pan Z; Yang L
Front Cell Dev Biol; 2021; 9():809516. PubMed ID: 35087837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
